# US 2014/0155323 A1 · Polypeptides, nucleic acid molecule encoding polypeptides, and uses of polypeptides > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0155323 A1 - Document ID: US20140155323A1 - Status: Published application - Kind: A1 - Application number: 14/160,791 - Filed: 2014-01-22 - Published: 2014-06-05 - Earliest claimed: 2012-05-18 - Assignees: China Medical University - Applicants: China Medical University - Inventors: Tin-Yun HO; Chien-Yun HSIANG - Web page: https://patentgrep.com/patent/US20140155323A1 ## CPC - A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)} - A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics - A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48) - A61P 3/10: for hyperglycaemia, e.g. antidiabetics - A61P 7/00: Drugs for disorders of the blood or the extracellular fluid - A61P 13/12: of the kidneys - C07K 7/06: having 5 to 11 amino acids - C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) - C07K 14/415: from plants - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) ## Abstract A polypeptide, a nucleic acid molecule encoding the polypeptide and a pharmaceutical composition comprising the polypeptide are provided. The polypeptide is as defined in the description, can bind to insulin receptors, and is effective in reducing blood sugar, reducing glycated hemoglobin, and ameliorating hepato-renal disorders caused by diabetes. ## Claims ### Claim 1 An isolated polypeptide consisting of the segmental amino acid sequence of SEQ ID NO:1 selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6. ### Claim 2 (depends on 1) The polypeptide as claimed in claim 1, wherein the segmental amino acid sequence of SEQ ID NO:1 is an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:6. ### Claim 3 An isolated polypeptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, and SEQ ID NO:188. ### Claim 4 (depends on 3) The polypeptide as claimed in claim 3, which has the amino acid sequence selected from the group consisting of SEQ ID NO:179, SEQ ID NO:184, SEQ ID NO:185, and SEQ ID NO:186. ### Claim 5 An isolated polypeptide consisting of the amino acid sequence of RYKYQX1X2YI (SEQ ID NO: 189) or a homologous amino acid sequence derived from the substitution of a single amino acid in SEQ ID NO: 189, wherein X1 is cysteine or tryptophan and X2 is phenylalanine or tryptophan. ### Claim 6 (depends on 5) The polypeptide as claimed in claim 5, which has the amino acid sequence of SEQ ID NO: 189. ### Claim 7 (depends on 5) The polypeptide as claimed in claim 5, wherein X1 is cysteine. ### Claim 8 (depends on 5) The polypeptide as claimed in claim 5, which has the amino acid sequence of RYKYQCFYI (SEQ ID NO: 191) or a homologous amino acid sequence derived from the substitution of a single amino acid in SEQ ID NO: 191, wherein the homologous amino acid sequence is the amino acid sequence selected from the group consisting of SEQ ID NO:194 to SEQ ID NO:364. ### Claim 9 (depends on 1) A vector containing a polynucleotide encoding the polypeptide as claimed in claim 1. ### Claim 10 (depends on 3) A vector containing a polynucleotide encoding the polypeptide as claimed in claim 3. ### Claim 11 (depends on 5) A vector containing a polynucleotide encoding the polypeptide as claimed in claim 5. ### Claim 12 (depends on 1) A method for at least one of reducing blood sugar, reducing glycated hemoglobin, and ameliorating hepato-renal disorders caused by diabetes in a subject, comprising administering to the subject an effective amount of the polypeptide as claimed in claim 1. ### Claim 13 (depends on 3) A method for at least one of reducing blood sugar, reducing glycated hemoglobin, and ameliorating hepato-renal disorders caused by diabetes in a subject, comprising administering to the subject an effective amount of the polypeptide as claimed in claim 3. ### Claim 14 (depends on 5) A method for at least one of reducing blood sugar, reducing glycated hemoglobin, and ameliorating hepato-renal disorders caused by diabetes in a subject, comprising administering to the subject an effective amount of the polypeptide as claimed in claim 5.